Piper Sandler analyst Matt O’Brien raised the firm’s price target on Sight Sciences to $5 from $2.50 and keeps a Neutral rating on the shares. The firm anticipates some concern around the political backdrop here in the U.S., but doubts med tech will be pressured regardless of who wins the Presidency. However, volumes and pricing for 2024 should be good across the sector. Piper sees little GLP related risk for the full year and anticipates 2024 will be a good year for med tech stocks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences sees FY23 revenue $80.9M-$81.1M, consensus $80.42M
- Sight Sciences sees Q4 revenue $18.6M to $18.8M , consensus $18.18M
- Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
- Piper says Sight Sciences reimbursement update positive, still sees ‘work to do’
- MIGS LCD withdrawals ‘takes some upside off table’ for Glaukos, says Truist